The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2023 | Novel approaches being explored for patients with accelerated and blast-phase MPNs
In this video, Jan Philipp Bewersdorf, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, shares some insights into novel approaches being explored for patients with accelerated and blast-phase (BP) myeloproliferative neoplasms (MPNs). Currently available options, including intensive chemotherapy and hypomethylating agent (HMA)-based therapy, often have poor outcomes, and Dr Bewersdorf highlights the potential role of combination approaches. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
